Non-cannabinoid molecule found to have anti-inflammatory effects

A newly-discovered, non-cannabinoid molecule, has demonstrated potent anti-inflammatory effects and is now being advanced into preclinical development.

Life sciences company, Juva Life has announced is proprietary, newly-discovered molecule, JUVA-019,  is being advanced into preclinical development to target inflammatory diseases.

JUVA-019 is a small, non-cannabinoid, purified molecule isolated from cannabis, which has been shown to have broad spectrum, anti-inflammatory properties.

Researchers at Juva have conducted multiple studies, including a previously announced comparative study that explored multiple modes of action for JUVA-019. These results have indicated that it is a potent modulator of TNF-alpha, IL-1 beta, and several other clinically relevant cytokines, and acts at known targets implicated in inflammation and diseases of ageing.

Additional laboratory studies suggest that the molecule is a potent stand-alone compound, and its anti-inflammatory activity is not dependent on synergism with other known cannabinoids.

Juva’s findings suggest that there are “unappreciated” molecules in cannabis, which could have clinical potential in a range of health conditions, according to founder and CEO, Doug Chloupek.

“We are excited about the nomination of JUVA-019 to formal development in which we will conduct detailed structure activity relationships on the JUVA-019 chemical motif to optimise its anti-inflammatory and drug-like properties,” stated Chloupek.

“This is an important advancement in the validation of our platform, in that it suggests that there are unappreciated non-cannabinoid molecules in cannabis that may be both clinically and commercially valuable.”

Sanjeev Gangwar PhD, vice president of chemistry at Juva, added: “Our next steps will follow the prescriptive advancement of JUVA-019 through the gold standard pre-clinical and non-clinical drug development process, initially focusing on exploring the structural requirements for activity.

“In parallel we will explore PD/PK relationships in a battery of in vivo models of human disease, with an initial focus on analgesia.”

Click here for more cannabis industry news